News Column

Psoriasis Market Identifying and Commercializing First-in-Class Innovation in New Research Report at LifeScienceIndustryResearch.com

June 1, 2014



Dallas, TX (PRWEB) June 01, 2014

Psoriasis is a chronic, inflammatory disease triggered by deregulated Thymus-derived (T) cells, resulting inflammation and benign hyperplasia of keratinocytes within the skin. Manifestations of affected skin are red, thickened plaques with an overlying silver-white scale, which significantly impairs the patient's physical and mental wellbeing. The primary cause of psoriasis is unknown, as are the mechanisms that lead to immune cells directing inflammatory responses towards the skin. Within the lucrative autoimmune market, the psoriasis market has grown considerably due to the repositioning of all three marketed Tumor Necrosis Factor (TNF) inhibitors: Humira (adalimumab) and Enbrel (etanercept) which were originally approved for rheumatoid arthritis, and also Remicade (infliximab), the first biologic to be approved for Crohn's disease, an autoimmune disease which largely affects the gastrointestinal system.

Complete report is available at http://www.lifescienceindustryresearch.com/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation.html.

Few Points from Table of Contents

5 First-in-Class Target and Pipeline Program Evaluation

5.1 Cytokines and Receptors

5.1.1 Pipeline Programs Targeting Tumor Necrosis Factor Receptors

5.1.2 Pipeline Programs Targeting Interleukin-6

5.1.3 Pipeline Programs Targeting Interleukin-8

5.1.4 Pipeline Programs Targeting Interleukin-17

5.1.5 Pipeline Programs Targeting Interferon-?

5.2 B and T Cell Antigens

5.2.1 Pipeline Programs Targeting Cluster of Differentiation 4

5.2.2 Pipeline Programs Targeting Cluster of Differentiation 28

5.3 Intracellular Kinases

5.3.1 Pipeline Programs Targeting Interleukin-1 Receptor-Associated Kinase-4

5.4 Nuclear Receptors

5.4.1 Pipeline Programs Targeting Retinoic Acid Receptor-Related Orphan Receptor

5.5 Growth Factors

5.5.1 Pipeline Programs Targeting Transforming Growth Factor-ß Receptor

5.5.2 Pipeline Programs Targeting Insulin Receptor Substrate

5.6 Ion Channels

5.6.1 Pipeline Programs Targeting Calcium Release-Activated Calcium Channel

5.7 Integrins

5.7.1 Pipeline Programs Targeting Vascular Adhesion Protein-1

5.8 Other

5.8.1 Pipeline Programs Targeting F1F0-Adenosine Triphosphate Synthase

5.8.2 Pipeline Programs Targeting Cathepsin S

5.9 Conclusion

6 Deals and Strategic Consolidations

6.1 Licensing Agreements

6.2 Major Co-development Deals

6.3 First-in-Class Developmental Programs Not Involved in Co-Development or Licensing Deals

List of Tables

Table 1: Psoriasis Market, Global, First-in-Class Interferon-? Inhibitors, Pipeline Development

Table 2: Psoriasis Market, Global, First-in-Class F1F0-Adenosine Triphosphate Synthase Modulators, Pipeline Development

Table 3: Abbreviations

List of Figures

Figure 1: Psoriasis, Global, Treatment Algorithm

Figure 2: Psoriasis Market, Global, Comparative Safety and Efficacy, 2013 - 1

Figure 3: Psoriasis Market, Global, Comparative Safety and Efficacy, 2013 - 2

Figure 4: Psoriasis Market, Global, Pipeline Overview, 2013

Figure 5: Psoriasis Market, Global, Comparative Safety and Efficacy of Pipeline Products, 2013

Figure 6: Psoriasis, Global, Comparative Distribution of Marketed and pipeline Products by Target Family

Figure 7: Psoriasis Market, Global, Pipeline, Comparative Distribution of Programs by Established and First-in-Class Targets, 2013

Figure 8: soriasis Market, Global, Pipeline Products with Established Targets, 2013

Figure 9: Psoriasis Market, Global, Pipeline Products with First-in-Class Targets, 2013

Figure 10: Psoriasis Market, Global, First-in-Class Tumor Necrosis Factor-a Receptor Modulators, Pipeline Development

Figure 11: Psoriasis Market, Global, First-in-Class Interleukin-6 Inhibitors, Pipeline Development

Figure 12: Psoriasis Market, Global, First-in-Class Interleukin-8 Inhibitors, Pipeline Development

Figure 13: Psoriasis Market, Global, First-in-Class Interleukin-17 Inhibitors, Pipeline Development

Figure 14: Psoriasis Market, Global, First-in-Class Cluster of Differentiation 4 Modulators, Pipeline Development

Figure 15: Psoriasis Market, Global, First-in-Class Cluster of Differentiation 28 Modulators, Pipeline Development

Figure 16: Psoriasis Market, Global, First-in-Class Interleukin-1 Receptor Associated Kinase-4 Inhibitors, Pipeline Development

Figure 17: Psoriasis Market, Global, First-in-Class Retinoic Acid Receptor-Related Orphan Receptor Inhibitors, Pipeline Development

Figure 18: Psoriasis Market, Global, First-in-Class Transforming Growth Factor-ß Receptor Modulators, Pipeline Development

Figure 19: Psoriasis Market, Global, First-in-Class Insulin Receptor Substrate Modulators, Pipeline Development

Figure 20: Psoriasis Market, Global, First-in-Class Calcium Release-Activated Calcium Channel, Pipeline Development

Figure 21: Psoriasis Market, Global, First-in-Class Vascular Adhesion Protein-1 Inhibitors, Pipeline Development

Figure 22: Psoriasis Market, Global, First-in-Class Cathepsin S Inhibitors, Pipeline Development

Figure 23: Psoriasis Market, Global, Licensing Agreement Analysis 1, 20062014

Figure 24: Psoriasis Market, Global, Licensing Agreement Analysis 2, 20062014

Figure 25: Psoriasis Market, Global, Licensing Agreement Deal Analysis, 20062014

Figure 26: Psoriasis Market, Global, Co-Development Deal Analysis, 20062014 - 1

Figure 27: Psoriasis Market, Global, Co-Development Deal Analysis, 20062014 - 2

Figure 28: Psoriasis Market, Global, First-in-Class Programs with no Recorded Prior Deal Involvement, 20062014

Purchase a copy of this report at http://www.lifescienceindustryresearch.com/purchase?rname=13805.

Browse more reports on Medical Devices Market at http://www.lifescienceindustryresearch.com/category/pharmaceuticals.

Contact sales(at)lifescienceindustryresearch(dot)com for further information.

About Us:

Life Science Industry Research is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, biotechnology, diagnostics, healthcare as well as medical devices and pharmaceuticals. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on sales(at)lifescienceindustryresearch(dot)com Phone and we would be happy to help you find the business intelligence that you need.

Read the full story at http://www.prweb.com/releases/psoriasis-identifying/commercializing-report/prweb11899811.htm


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: PR Web